AstraZeneca Gets a Boost From Sales of Its Cancer Drugs

Key TakeawaysAstraZeneca's sales of cancer drugs helped the pharmaceutical firm beat first-quarter estimates for earnings and revenue.Sales of oncology treatments rose 23%, and those for medicines made with partners jumped 59%.American depositary receipts (ADRs) of AstraZeneca traded near their all-time high on the news. American depositary receipts (ADRs) of AstraZeneca (AZN) traded near their all-time high as the Anglo-Swedish pharmaceutical company had solid first-quarter demand for its cancer drugs. Ast ...